CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• AES stockholders approve $10.7 billion takeover by GIP and EQT
• Tractor Supply and Starlink team up to expand rural broadband via 4-H